U.S. Markets open in 1 hr 12 mins
  • S&P Futures

    3,459.25
    +10.00 (+0.29%)
     
  • Dow Futures

    28,355.00
    +87.00 (+0.31%)
     
  • Nasdaq Futures

    11,672.25
    +22.50 (+0.19%)
     
  • Russell 2000 Futures

    1,639.50
    +8.90 (+0.55%)
     
  • Crude Oil

    40.74
    +0.10 (+0.25%)
     
  • Gold

    1,914.30
    +9.70 (+0.51%)
     
  • Silver

    24.89
    +0.18 (+0.71%)
     
  • EUR/USD

    1.1864
    +0.0038 (+0.3203%)
     
  • 10-Yr Bond

    0.8480
    0.0000 (0.00%)
     
  • Vix

    27.60
    -1.05 (-3.66%)
     
  • GBP/USD

    1.3079
    -0.0001 (-0.0052%)
     
  • USD/JPY

    104.7260
    -0.1140 (-0.1087%)
     
  • BTC-USD

    12,947.50
    -19.24 (-0.15%)
     
  • CMC Crypto 200

    261.42
    +5.32 (+2.08%)
     
  • FTSE 100

    5,874.72
    +89.07 (+1.54%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that members of the management team will present at two upcoming investor conferences:

  • Barclays Global Healthcare Conference on Wednesday, March 11 at 3:20 p.m. ET in Miami.

  • Oppenheimer 30th Annual Healthcare Conference on Wednesday, March 18 at 8:35 a.m. ET in New York.

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com